ASLAN003

DRUG2 trials

Sponsors

ASLAN Pharmaceuticals

Conditions

Acute Myeloid LeukemiaHealthy Elderly Subjects (Age ≥55 Years)

Phase 1

A Phase 1, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASLAN003 in Healthy Elderly Subjects

CompletedNCT02342652

ASLAN PharmaceuticalsHealthy Elderly Subjects (Age ≥55 Years)

Start: 2014-10-31End: 2015-03-31Updated: 2016-11-02

Phase 2

A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia

CompletedNCT03451084

ASLAN PharmaceuticalsAcute Myeloid Leukemia

Start: 2018-01-05End: 2019-12-13Updated: 2021-07-06

Related Papers

Preliminary Results of a Phase 2a Dose Optimization Study of ASLAN003 (DHODH inhibitor) in Acute Myeloid Leukemia (AML) Patients Who Are Ineligible for Standard Therapy; Early Signs of Activity

Blood2018-11-297 citations

ASLAN003, a Novel and Potent Dihydroorotate Dehydrogenase (DHODH) Inhibitor, Induces Differentiation of Acute Myeloid Leukemia

Blood2018-11-293 citations

A phase IIA dose optimization study of ASLAN003 in acute myeloid leukemia (AML)

Annals of Oncology2018-10-012 citations